Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing

Journal of Clinical Pathology

Volumn 57, Issue 11, 2004, Pages 1140-1144

  Kay, E ^a   O'Grady, A ^a   Morgan, J M ^b   Wozniak, S ^b   Jasani, B ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA MICROARRAY; EVALUATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOGENE NEU; PRIORITY JOURNAL; STANDARDIZATION; TISSUE SECTION; VALIDATION PROCESS; WORKLOAD;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; TISSUE ARRAY ANALYSIS;

EID: 8444225812     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.014910     Document Type: Article

References (12)

1. National Institute for Clinical Excellence. Technology appraisal No 34. Guidance on the use of trastuzumab for the treatment of advanced breast cancer 2002 (http://www.nice.org.uk/article.asp?a=29280).
2. Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000;53:890-2.
3. Ellis IO, Bartlett J, Dowsett M, et al. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004;57:233-7.
4. O'Grady A, Flahavan CM, Kay EW, et al. HER-2 analysis in tissue microarrays of archival human breast cancer: comparison of immunohistochemistry and fluorescence in-situ hybridisation. Appl Immunohistochem Mol Morphol 2003;11:177-82.
5. Zhang D, Salto-Tellez M, DoE, et al. Evaluation of HER2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 2003;34:362-8.
6. Kononen J, Babendorf L, Kallioniemi, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
7. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER-2 testing-national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002;94:852-4.
8. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001;158:1245-51.
9. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
10. Rhodes A, Jasani B, Courturier J, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002;117:81-9.
11. Ginestier C, Charafe-Jauffret E, Penault-Llorca F, et al. Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol 2004;202:286-98.
12. Yazijt H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol 2004;35:143-6.